Bristol Myers’ acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol …

Pfizer is building up its pipeline of experimental cancer medicines, announcing Monday a deal to buy the Cambridge, Massachusetts-based biotech Trillium Therapeutics for nearly $2.3 …

Peloton was one of a handful of cancer-focused biotech companies acquired since 2018 by Merck, which has sought to complement its top-selling immunotherapy Keytruda with …

GSK has high hopes for Jemperli as it transitions to what’s being called the “new GSK,” with a greater focus on experimental drugs for infectious …

Facing increased competition for many of its top-selling drugs, Amgen is focusing on building its pipeline of drugs for the future, especially in the areas …